Chang P, Méndez E

Language: Spanish
References: 13
Page: 245-248
PDF size: 694.72 Kb.

ABSTRACT

Antecedents: Nail diseases by cytostatic in children.
Objectives: to report the clinical experience of nail diseases in children due to cytostatic drugs.
Methods: We carried out a transversal study to find out the frequency of patients from the Hematooncology Service of the Pediatrics General Hospital IGSS. Neither age nor sex or diseases were used as criteria for the inclusion of a patient in the study, which took place during the months of September and October 2009. We performed dermatological examination on fingernails and toenails of all patients.
Results: We studied 20 patients; 13 were male (65%) and 7 (35%) female. In only 10 (50%) we found nail changes secondary to chemotherapy. Patients that showed abnormalities on fingernails and toenails totaled 5 (25%), 3 on fingernails (15%), and 2 on toenails (10%). We found fingernail dyschromia of the proximal fingernail fold in 4 cases (20%), Muehrcke bands in 2 (20%), melanonychia in 1 (10%), and Beau’s lines in 2 (20%). And we found toenail dyschromia of the proximal toenail fold in 3 cases, Muehrcke bands in 3 (30%), Beau’s lines in 3 (30%), and leukonychia in 1 (10%).
Conclusions: Nail changes by cytostatic drugs occur in children and go unnoticed due to ignorance, and because diseases of the nail apparatus are not given importance.

REFERENCES

1. Mitchell A, Lacouture PG, Sheehan JE, Kauffman RE, Shapiro S. “Adverse drug reactions in children leading to hospital admission”. Pediatrics 1988; 82 (1): 24-29.

2. Chang P, Samcam Navarrete ME. “Onicopatías por docetaxel”. Dermatología Cosmética, Médica y Quirúrgica 2007; 5 (2): 92-95.

3. Martindale: the complete drug reference (33rd edition). Eds, Sweetman, et al. Pharmaceutical Press, 2002 The Complete Drug Reference. 33a edición. Pharmaceutical Press, 2002.

4. British National Formulary, (46th edition). British Medical Association and Royal Pharmaceutical Society of Great Britain, September 2003.

5. Perry MC. The Chemotherapy Source Book. 3ª edición. Lippincott Williams and Wilkins, 2001.

6. Seibel NL, Blaney SM, O’Brien M, Krailo M, Hutchinson R, Mosher RB, et al. “Phase I Trial of Docetaxel with Filgrastim Support in Pediatric Patients with Refractory Solid Tumors: Collaborative Pediatric Oncology Branch, National Cancer Institute and Childrens Cancer Group Trial”. Clinical Cancer Research 1999; 5: 733-737.

7. Hinds G, Thomas VD. “Malignancy and cancer treatment-related hair and nail changes”. Dermatol Clin 2008; 26: 59-68.

8. Pronk LC, Stoter G, Verweij J. “Docetaxel (Taxotere): Single agent activity, development of combination treatment and reaction side effects”. Cancer Treatment Reviews 1995; 21: 463-478.

9. Gupta A, Parakh A, Dubey AP. “Chemotherapy induced nail changes”. Indian J Dermatol 2008; 53: 204-205.

10. Yoruk A, Yukselgungor H. “Chemotherapy induced transverse Leukonychia in children”. International Journal of Dermatology 2003; 42: 468-469.

11. Dasanu CA, Alexandrescu DT, Wiernik PH. “Recognizing nail and skin changes associated with chemotherapy”. Resident and Staff Physician; 2006: 52

12. Dasanu CA, Vaillant JG, Alexandrescu DT. “Distinct patterns of chromonychia, Beau’s lines and melanoderma seen with vincristine, adriamycin, dexamethasone for multiple myeloma”. Dermatol Online J 2006; 12: 10.

13. Chen W, Yu YS, Liu YH, Sheen JM, Hsiao CC. “Nail changes associated with chemotherapy in children”. Journal of the European Academy of Dermatology and Venereology 2006; 21(2): 186-190.